Targeting apoptosis pathways by Celecoxib in cancer

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 313-324

  Jendrossek, Verena ^a  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

Apoptosis; Bcl 2; Celecoxib; COX 2; Mcl 1

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 2,5 DIMETHYLCELECOXIB; ANTINEOPLASTIC AGENT; BETA CATENIN; CALCIUM ION; CASPASE 8; CELECOXIB; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; IBUPROFEN; NAPROXEN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE R; PROTEIN MCL 1; PROTEIN NOXA; ROFECOXIB; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SURVIVIN; UNCLASSIFIED DRUG; VALDECOXIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; CALCIUM CELL LEVEL; CANCER INHIBITION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL CYCLE ARREST; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CHEMORADIOTHERAPY; COLON CANCER; CONFORMATIONAL TRANSITION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GASTROINTESTINAL SYMPTOM; HUMAN; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SHORT SURVEY;

EID: 84876078256     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.012     Document Type: Review

References (143)

1. Brown J.R., DuBois R.N. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 2005, 23:2840-2855.
2. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18:7908-7916.
3. Gupta S., Srivastava M., Ahmad N., Bostwick D.G., Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000, 42:73-78.
4. Soslow R.A., Dannenberg A.J., Rush D., Woerner B.M., Khan K.N., Masferrer J., Koki A.T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000, 89:2637-2645.
5. Ladetto M., Vallet S., Trojan A., Dell'Aquila M., Monitillo L., Rosato R., Santo L., Drandi D., Bertola A., Falco P., Cavallo F., Ricca I., De Marco F., Mantoan B., Bode-Lesniewska B., Pagliano G., Francese R., Rocci A., Astolfi M., Compagno M., Mariani S., Godio L., Marino L., Ruggeri M., Omede P., Palumbo A., Boccadoro M. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 2005, 105:4784-4791.
6. Ferrandina G., Lauriola L., Distefano M.G., Zannoni G.F., Gessi M., Legge F., Maggiano N., Mancuso S., Capelli A., Scambia G., Ranelletti F.O. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J. Clin. Oncol. 2002, 20:973-981.
7. Liu H., Yang Y., Xiao J., Lv Y., Liu Y., Yang H., Zhao L. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C. Anat. Rec. (Hoboken) 2009, 292:1577-1583.
8. Phillips R.K., Wallace M.H., Lynch P.M., Hawk E., Gordon G.B., Saunders B.P., Wakabayashi N., Shen Y., Zimmerman S., Godio L., Rodrigues-Bigas M., Su L.K., Sherman J., Kelloff G., Levin B., Steinbach G. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002, 50:857-860.
9. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006, 355:885-895.
10. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342:1946-1952.
11. Williams C.S., Watson A.J., Sheng H., Helou R., Shao J., DuBois R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 2000, 60:6045-6051.
12. El-Rayes B.F., Ali S., Sarkar F.H., Philip P.A. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol. Cancer Ther. 2004, 3:1421-1426.
13. Johnsen J.I., Lindskog M., Ponthan F., Pettersen I., Elfman L., Orrego A., Sveinbjornsson B., Kogner P. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res. 2004, 64:7210-7215.
14. Muller A.C., Handrick R., Elsaesser S.J., Rudner J., Henke G., Ganswindt U., Belka C., Jendrossek V. Importance of Bak for celecoxib-induced apoptosis. Biochem. Pharmacol. 2008, 76:1082-1096.
15. Waskewich C., Blumenthal R.D., Li H., Stein R., Goldenberg D.M., Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002, 62:2029-2033.
16. Kim Y.Y., Lee E.J., Kim Y.K., Kim S.M., Park J.Y., Myoung H., Kim M.J. Anti-cancer effects of celecoxib in head and neck carcinoma. Mol. Cells 2010, 29:185-194.
17. Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., Sugiura T., Ogawa M., Takahashi T. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 2000, 6:2006-2011.
18. Trifan O.C., Durham W.F., Salazar V.S., Horton J., Levine B.D., Zweifel B.S., Davis T.W., Masferrer J.L. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 2002, 62:5778-5784.
19. Sandler A.B., Dubinett S.M. COX-2 inhibition and lung cancer. Semin. Oncol. 2004, 31:45-52.
20. Milas L., Kishi K., Hunter N., Mason K., Masferrer J.L., Tofilon P.J. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. 1999, 91:1501-1504.
21. Davis T.W., O'Neal J.M., Pagel M.D., Zweifel B.S., Mehta P.P., Heuvelman D.M., Masferrer J.L. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res. 2004, 64:279-285.
22. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin. Oncol. (R Coll. Radiol.) 2007, 19:397-417.
23. Grosch S., Maier T.J., Schiffmann S., Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 2006, 98:736-747.
24. Jendrossek V., Handrick R., Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J. 2003, 17:1547-1549.
25. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., Chen C.S. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J. Natl. Cancer Inst. 2002, 94:585-591.
26. Grosch S., Tegeder I., Niederberger E., Brautigam L., Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001, 15:2742-2744.
27. Leahy K.M., Ornberg R.L., Wang Y., Zweifel B.S., Koki A.T., Masferrer J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002, 62:625-631.
28. Lin H.P., Kulp S.K., Tseng P.H., Yang Y.T., Yang C.C., Chen C.S. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol. Cancer Ther. 2004, 3:1671-1680.
29. Schiffmann S., Maier T.J., Wobst I., Janssen A., Corban-Wilhelm H., Angioni C., Geisslinger G., Grosch S. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem. Pharmacol. 2008, 76:179-187.
30. Tan T.T., White E. Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells. Adv. Exp. Med. Biol. 2008, 615:81-104.
31. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
32. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
33. Wilson T.R., Johnston P.G., Longley D.B. Anti-apoptotic mechanisms of drug resistance in cancer. Curr. Cancer Drug Targets 2009, 9:307-319.
34. de Bruin E.C., Medema J.P. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat. Rev. 2008, 34:737-749.
35. Weinmann M., Jendrossek V., Guner D., Goecke B., Belka C. Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways. FASEB J. 2004, 18:1906-1908. (Epub 2004 Sep 28).
36. Belka C., Jendrossek V., Pruschy M., Vink S., Verheij M., Budach W. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:542-554.
37. Chuang H.C., Kardosh A., Gaffney K.J., Petasis N.A., Schonthal A.H. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol. Cancer 2008, 7:38.
38. Zhu J., Huang J.W., Tseng P.H., Yang Y.T., Fowble J., Shiau C.W., Shaw Y.J., Kulp S.K., Chen C.S. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004, 64:4309-4318.
39. Arico S., Pattingre S., Bauvy C., Gane P., Barbat A., Codogno P., Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer cell line HT-29. J. Biol. Chem. 2002, 8:8.
40. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 2000, 275:11397-11403.
41. Pyrko P., Soriano N., Kardosh A., Liu Y.T., Uddin J., Petasis N.A., Hofman F.M., Chen C.S., Chen T.C., Schonthal A.H. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol. Cancer 2006, 5:19.
42. Rudner J., Elsaesser S.J., Muller A.C., Belka C., Jendrossek V. Differential effects of anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2, and Bcl-xL on celecoxib-induced apoptosis. Biochem. Pharmacol. 2010, 79:10-20.
43. Johnson A.J., Hsu A.L., Lin H.P., Song X., Chen C.S. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem. J. 2002, 366:831-837.
44. Patel M.I., Subbaramaiah K., Du B., Chang M., Yang P., Newman R.A., Cordon-Cardo C., Thaler H.T., Dannenberg A.J. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin. Cancer Res. 2005, 11:1999-2007.
45. Schonthal A.H. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br. J. Cancer 2007, 97:1465-1468.
46. Pyrko P., Kardosh A., Liu Y.T., Soriano N., Xiong W., Chow R.H., Uddin J., Petasis N.A., Mircheff A.K., Farley R.A., Louie S.G., Chen T.C., Schonthal A.H. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2, 5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol. Cancer Ther. 2007, 6:1262-1275.
47. Pyrko P., Kardosh A., Schonthal A.H. Celecoxib transiently inhibits cellular protein synthesis. Biochem. Pharmacol. 2008, 75:395-404.
48. Tsutsumi S., Namba T., Tanaka K.I., Arai Y., Ishihara T., Aburaya M., Mima S., Hoshino T., Mizushima T. Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells. Oncogene 2006, 25:1018-1029.
49. Basu G.D., Pathangey L.B., Tinder T.L., Lagioia M., Gendler S.J., Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol. Cancer Res. 2004, 2:632-642.
50. Narayanan B.A., Narayanan N.K., Pittman B., Reddy B.S. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin. Cancer Res. 2004, 10:7727-7737.
51. Maier T.J., Schiffmann S., Wobst I., Birod K., Angioni C., Hoffmann M., Lopez J.J., Glaubitz C., Steinhilber D., Geisslinger G., Grosch S. Cellular membranes function as a storage compartment for celecoxib. J. Mol. Med. 2009, 87:981-993.
52. Lin M.T., Lee R.C., Yang P.C., Ho F.M., Kuo M.L. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 2001, 276:48997-49002.
53. Patel V.A., Dunn M.J., Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem. 2002, 277:38915-38920.
54. Schonthal A.H. Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg. Focus 2006, 20:E21.
55. Kulp S.K., Yang Y.T., Hung C.C., Chen K.F., Lai J.P., Tseng P.H., Fowble J.W., Ward P.J., Chen C.S. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004, 64:1444-1451.
56. Wobst I., Schiffmann S., Birod K., Maier T.J., Schmidt R., Angioni C., Geisslinger G., Grosch S. Dimethylcelecoxib inhibits prostaglandin E2 production. Biochem. Pharmacol. 2008, 76:62-69.
57. Deckmann K., Rorsch F., Steri R., Schubert-Zsilavecz M., Geisslinger G., Grosch S. Dimethylcelecoxib inhibits mPGES-1 promoter activity by influencing EGR1 and NF-kappaB. Biochem. Pharmacol. 2010, 80:1365-1372.
58. Lev-Ari S., Kazanov D., Liberman E., Ben-Yosef R., Arber N. Down-regulation of PGE2 by physiologic levels of celecoxib is not sufficient to induce apoptosis or inhibit cell proliferation in human colon carcinoma cell lines. Dig. Dis. Sci. 2007, 52:1128-1133.
59. Wu T., Leng J., Han C., Demetris A.J. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol. Cancer Ther. 2004, 3:299-307.
60. Komatsu K., Buchanan F.G., Katkuri S., Morrow J.D., Inoue H., Otaka M., Watanabe S., DuBois R.N. Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Gastroenterology 2005, 129:577-590.
61. Seno H., Oshima M., Ishikawa T.O., Oshima H., Takaku K., Chiba T., Narumiya S., Taketo M.M. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 2002, 62:506-511.
62. Kern M.A., Haugg A.M., Koch A.F., Schilling T., Breuhahn K., Walczak H., Fleischer B., Trautwein C., Michalski C., Schulze-Bergkamen H., Friess H., Stremmel W., Krammer P.H., Schirmacher P., Muller M. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res. 2006, 66:7059-7066.
63. Liu X., Yue P., Zhou Z., Khuri F.R., Sun S.Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J. Natl. Cancer Inst. 2004, 96:1769-1780.
64. Ding H., Han C., Zhu J., Chen C.S., D'Ambrosio S.M. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int. J. Cancer 2005, 113:803-810.
65. U. Sinha-Datta, J.M. Taylor, M. Brown, C. Nicot, Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt. Apoptosis (2007).
66. Kucab J.E., Lee C., Chen C.S., Zhu J., Gilks C.B., Cheang M., Huntsman D., Yorida E., Emerman J., Pollak M., Dunn S.E. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 2005, 7:R796-R807. (Epub 2005 Aug 1).
67. Belka C., Rudner J., Wesselborg S., Stepczynska A., Marini P., Lepple-Wienhues A., Faltin H., Bamberg M., Budach W., Schulze-Osthoff K. Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis. Oncogene 2000, 19:1181-1190.
68. Alloza I., Baxter A., Chen Q., Matthiesen R., Vandenbroeck K. Celecoxib inhibits interleukin-12 alphabeta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum. Mol. Pharmacol. 2006, 69:1579-1587.
69. Tsutsumi S., Gotoh T., Tomisato W., Mima S., Hoshino T., Hwang H.J., Takenaka H., Tsuchiya T., Mori M., Mizushima T. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ. 2004, 11:1009-1016.
70. Kardosh A., Golden E.B., Pyrko P., Uddin J., Hofman F.M., Chen T.C., Louie S.G., Petasis N.A., Schonthal A.H. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res. 2008, 68:843-851.
71. Wu J., Kaufman R.J. From acute ER stress to physiological roles of the unfolded protein respons. Cell Death Differ. 2006, 13:374-384.
72. Rasheva V.I., Domingos P.M. Cellular responses to endoplasmic reticulum stress and apoptosis. Apoptosis 2009, 14:996-1007.
73. Kim S.H., Hwang C.I., Juhnn Y.S., Lee J.H., Park W.Y., Song Y.S. GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. Carcinogenesis 2007, 28:223-231.
74. Tanaka K., Tomisato W., Hoshino T., Ishihara T., Namba T., Aburaya M., Katsu T., Suzuki K., Tsutsumi S., Mizushima T. Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J. Biol. Chem. 2005, 280:31059-31067. (Epub 2005 Jun 29).
75. Cianchi F., Cortesini C., Magnelli L., Fanti E., Papucci L., Schiavone N., Messerini L., Vannacci A., Capaccioli S., Perna F., Lulli M., Fabbroni V., Perigli G., Bechi P., Masini E. Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol. Cancer Ther. 2006, 5:2716-2726.
76. Fantappie O., Solazzo M., Lasagna N., Platini F., Tessitore L., Mazzanti R. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res. 2007, 67:4915-4923.
77. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
78. Hemmati P.G., Guner D., Gillissen B., Wendt J., von Haefen C., Chinnadurai G., Dorken B., Daniel P.T. Bak functionally complements for loss of Bax during p14ARF-induced mitochondrial apoptosis in human cancer cells. Oncogene 2006, 25:6582-6594.
79. Reed J.C. Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 2006, 13:1378-1386.
80. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
81. Wang G.Q., Gastman B.R., Wieckowski E., Goldstein L.A., Gambotto A., Kim T.H., Fang B., Rabinovitz A., Yin X.M., Rabinowich H. A role for mitochondrial Bak in apoptotic response to anticancer drugs. J. Biol. Chem. 2001, 276:34307-34317.
82. Johnson A.J., Smith L.L., Zhu J., Heerema N.A., Jefferson S., Mone A., Grever M., Chen C.S., Byrd J.C. A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. Blood 2005, 105:2504-2509.
83. Michels J., O'Neill J.W., Dallman C.L., Mouzakiti A., Habens F., Brimmell M., Zhang K.Y., Craig R.W., Marcusson E.G., Johnson P.W., Packham G. Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene 2004, 23:4818-4827.
84. Opferman J.T. Unraveling MCL-1 degradation. Cell Death Differ. 2006, 13:1260-1262.
85. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., Huang D.C. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 2005, 17:393-403.
86. Willis S.N., Chen L., Dewson G., Wei A., Naik E., Fletcher J.I., Adams J.M., Huang D.C. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19:1294-1305.
87. Zhong Q., Gao W., Du F., Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005, 121:1085-1095.
88. Craig R.W. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002, 16:444-454.
89. Kuo M.L., Chuang S.E., Lin M.T., Yang S.Y. The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 2001, 20:677-685.
90. Maurer U., Charvet C., Wagman A.S., Dejardin E., Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 2006, 21:749-760.
91. Dai H., Meng X.W., Lee S.H., Schneider P.A., Kaufmann S.H. Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis. J. Biol. Chem. 2009, 284:18311-18322.
92. Han J., Goldstein L.A., Gastman B.R., Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J. Biol. Chem. 2006, 281:10153-10163.
93. Zhou P., Qian L., Bieszczad C.K., Noelle R., Binder M., Levy N.B., Craig R.W. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 1998, 92:3226-3239.
94. Certo M., Del Gaizo Moore V., Nishino M., Wei G., Korsmeyer S., Armstrong S.A., Letai A. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006, 9:351-365.
95. Del Bello B., Valentini M.A., Zunino F., Comporti M., Maellaro E. Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Oncogene 2001, 20:4591-4595.
96. Yamamoto K., Ichijo H., Korsmeyer S.J. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol. Cell Biol. 1999, 19:8469-8478.
97. Wei Y., Pattingre S., Sinha S., Bassik M., Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol. Cell 2008, 30:678-688.
98. Pattingre S., Bauvy C., Carpentier S., Levade T., Levine B., Codogno P. Role of JNK1-dependent Bcl-2 phosphorylation in ceramide-induced macroautophagy. J. Biol. Chem. 2009, 284:2719-2728.
99. Lin B., Kolluri S.K., Lin F., Liu W., Han Y.H., Cao X., Dawson M.I., Reed J.C., Zhang X.K. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004, 116:527-540.
100. Thompson J., Winoto A. Nur77 family proteins translocate to mitochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain. J. Exp. Med. 2008, 205:1029-1036.
101. Subhashini J., Mahipal S.V., Reddanna P. Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett. 2005, 224:31-43.
102. Chen J.C., Chen Y., Su Y.H., Tseng S.H. Celecoxib increased expression of 14-3-3sigma and induced apoptosis of glioma cells. Anticancer Res. 2007, 27:2547-2554.
103. Sattler M., Liang H., Nettesheim D., Meadows R.P., Harlan J.E., Eberstadt M., Yoon H.S., Shuker S.B., Chang B.S., Minn A.J., Thompson C.B., Fesik S.W. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997, 275:983-986.
104. Cuconati A., Mukherjee C., Perez D., White E. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev. 2003, 17:2922-2932.
105. Zhai D., Jin C., Huang Z., Satterthwait A.C., Reed J.C. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J. Biol. Chem. 2008, 283:9580-9586.
106. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., Ierino H., Lee E.F., Fairlie W.D., Bouillet P., Strasser A., Kluck R.M., Adams J.M., Huang D.C. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007, 315:856-859.
107. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., Willis S.N., Scott C.L., Day C.L., Cory S., Adams J.M., Roberts A.W., Huang D.C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
108. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
109. Huang S., Sinicrope F.A. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy 2010, 6:255-269.
110. Kardosh A., Soriano N., Pyrko P., Liu Y.T., Jabbour M., Hofman F.M., Schonthal A.H. Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib. J. Biomed. Sci. 2007, 14:647-662.
111. Hsiao P.W., Chang C.C., Liu H.F., Tsai C.M., Chiu T.H., Chao J.I. Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicol. Appl. Pharmacol. 2007, 222:97-104.
112. Fukada K., Takahashi-Yanaga F., Sakoguchi-Okada N., Shiraishi F., Miwa Y., Morimoto S., Sasaguri T. Celecoxib induces apoptosis by inhibiting the expression of survivin in HeLa cells. Biochem. Biophys. Res. Commun. 2007, 357:1166-1171.
113. Catalano A., Graciotti L., Rinaldi L., Raffaelli G., Rodilossi S., Betta P., Gianni W., Amoroso S., Procopio A. Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int. J. Cancer 2004, 109:322-328.
114. Sakoguchi-Okada N., Takahashi-Yanaga F., Fukada K., Shiraishi F., Taba Y., Miwa Y., Morimoto S., Iida M., Sasaguri T. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem. Pharmacol. 2007, 73:1318-1329.
115. Altieri D.C. New wirings in the survivin networks. Oncogene 2008, 27:6276-6284.
116. Bai X.M., Jiang H., Ding J.X., Peng T., Ma J., Wang Y.H., Zhang L., Zhang H., Leng J. Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells. Life Sci. 2010, 86:214-223.
117. Mehar A., Macanas-Pirard P., Mizokami A., Takahashi Y., Kass G.E., Coley H.M. The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents. J. Pharmacol. Exp. Ther. 2008, 324:1181-1187.
118. Zhao S., Cai J., Bian H., Gui L., Zhao F. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin. Cancer Invest. 2009, 27:636-640.
119. Gaiser T., Becker M.R., Habel A., Reuss D.E., Ehemann V., Rami A., Siegelin M.D. TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin. Neurosci. Lett. 2008, 442:109-113.
120. Maier T.J., Janssen A., Schmidt R., Geisslinger G., Grosch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J. 2005, 19:1353-1355.
121. Tuynman J.B., Vermeulen L., Boon E.M., Kemper K., Zwinderman A.H., Peppelenbosch M.P., Richel D.J. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008, 68:1213-1220.
122. Tan Y.H., Lee K.H., Lin T., Sun Y.C., Hsieh-Li H.M., Juan H.F., Wang Y.C. Cytotoxicity and proteomics analyses of OSU03013 in lung cancer. Clin. Cancer Res. 2008, 14:1823-1830.
123. J.J. Xia, L.B. Pei, J.P. Zhuang, Y. Ji, G.P. Xu, Z.P. Zhang, N. Li, J.L. Yan, Celecoxib inhibits beta-catenin-dependent survival of the human osteosarcoma MG-63 cell line, J. Int. Med. Res. 38 1294-1304.
124. F. Takahashi-Yanaga, M. Kahn, Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin. Cancer Res. 16 3153-3162.
125. Fodde R., Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 2007, 19:150-158.
126. Tegeder I., Niederberger E., Israr E., Guhring H., Brune K., Euchenhofer C., Grosch S., Geisslinger G. Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. FASEB J. 2001, 15:595-597.
127. Grosch S., Tegeder I., Schilling K., Maier T.J., Niederberger E., Geisslinger G. Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. FASEB J. 2003, 17:1316-1318.
128. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., Anderson W.F., Zauber A., Hawk E., Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 2005, 352:1071-1080.
129. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. Jama 2001, 286:954-959.
130. Fitzgerald G.A. Coxibs and cardiovascular disease. N. Engl. J. Med. 2004, 351:1709-1711.
131. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., Baron J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 2005, 352:1092-1102.
132. Sooriakumaran P., Langley S.E., Laing R.W., Coley H.M. COX-2 inhibition: a possible role in the management of prostate cancer?. J. Chemother. 2007, 19:21-32.
133. Schonthal A.H., Chen T.C., Hofman F.M., Louie S.G., Petasis N.A. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin. Investig. Drugs 2008, 17:197-208.
134. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. Jama 2006, 296:1633-1644.
135. Zhu J., Song X., Lin H.P., Young D.C., Yan S., Marquez V.E., Chen C.S. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J. Natl. Cancer Inst. 2002, 94:1745-1757.
136. Kardosh A., Soriano N., Liu Y.T., Uddin J., Petasis N.A., Hofman F.M., Chen T.C., Schonthal A.H. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 2005, 106:4330-4338. (Epub 2005 Aug 25).
137. Denkert C., Winzer K.J., Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin. Breast Cancer 2004, 4:428-433.
138. Bundred N.J., Barnes N.L. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br. J. Cancer 2005, 93:S10-S15.
139. Lim S.C., Lee T.B., Choi C.H., Ryu S.Y., Min Y.D., Kim K.J. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J. Surg. Oncol. 2008, 97:51-56.
140. Kim Y.B., Kim G.E., Cho N.H., Pyo H.R., Shim S.J., Chang S.K., Park H.C., Suh C.O., Park T.K., Kim B.S. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 2002, 95:531-539.
141. Chen W.C., McBride W.H., Chen S.M., Lee K.F., Hwang T.Z., Jung S.M., Shau H., Liao S.K., Hong J.H., Chen M.F. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies. Head Neck 2005, 27:503-512.
142. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 2008, 9:47-59.
143. Kuwana T., Bouchier-Hayes L., Chipuk J.E., Bonzon C., Sullivan B.A., Green D.R., Newmeyer D.D. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 2005, 17:525-535.